Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Heart and Vessels
Metadata
Title
Neurofibromatosis as a cause of multiple coronary aneurysms
Authors
Tuba Bilsel
Tamer Akbulut
Sait Terzi
Nurten Sayar
Kemal Yesilcimen
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Heart and Vessels / Issue 3/2005
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-004-0806-4

Other articles of this Issue 3/2005

Heart and Vessels 3/2005 Go to the issue

ORIGINAL ARTICLE

Management of 28 consecutive iatrogenic femoral pseudoaneurysms with ultrasound-guided compression

ORIGINAL ARTICLE

The relation between endothelin-1 levels and myocardial injury in chronic ischemic heart failure

ORIGINAL ARTICLE

Increased thrombolysis in myocardial infarction (TIMI) frame count in patients with aortic stenosis but normal coronary arteries

CASE REPORT

Takotsubo-shaped cardiomyopathy with type I CD36 deficiency

ORIGINAL ARTICLE

Characteristics of ischaemic human myocardium: a transoesophageal echocardiographic and voltammetric microelectrode study

ORIGINAL ARTICLE

Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits